HomeStartups Clearmind Medicine lifecycle

Claimed by owner Last Update Jun 9, 2026 Suggest Edits Claim Profile

Claimed by owner

Clearmind Medicine

Treatments for Binge Behavior and Mental Health

PUBLIC on CSE on Jun 2022

PUBLIC on NASDAQ on Nov 2022

Clearmind Medicine

Clearmind Medicine Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Why Did CMND Stock Jump 40% Today?

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts

Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans?

Clearmind Medicine Announces 1-for-10 Reverse Share Split

Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND)

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain

Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Trump Trade: President to sign order on psychedelic used for PTSD

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

#Product Stage #FDA approved/pending approval

/PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments,...

#Product Stage #Partners

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

#Product Stage

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#PIPE #Investment

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

#Product Stage

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Product Stage #Customers

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

#Partners #Product Stage

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

#Partners #Product Stage

Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

#Product Stage

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

#Product Stage

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

#Product Stage #FDA approved/pending approval

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

#Product Stage #FDA approved #Partners

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

#Product Stage

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Acquisition

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

#Product Stage

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

BC-Most Active Stocks

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

#Product Stage

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

#Product Stage #Customers

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

#Product Stage #Customers

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

#Product Stage

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Product Stage #Customers

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

#Product Stage #FDA approved/pending approval

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

#Product Stage

BC-Most Active Stocks

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

#Product Stage #Partners

BC-Most Active Stocks

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

#Product Stage #FDA approved/pending approval

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

#Product Stage

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

#Product Stage #FDA approved/pending approval

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

#Investment #PIPE/PO

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

#Product Stage #FDA approved/pending approval

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Acquired-by #Acquisition

Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy

#Product Stage #Public Trading

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

#Product Stage #FDA approved/pending approval

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

#Product Stage

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

#Management Changes #Partners #Product Stage

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

#Product Stage #Customers

Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

#Product Stage #Partners

Clearmind Medicine Signs Deal to Raise Up to $10 Million Through Convertible Notes

#Investment

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

#Investment

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

#Product Stage #Partners

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

#Product Stage #FDA approved/pending approval

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

#Product Stage #Partners

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

#Product Stage #Partners

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

#Product Stage #Customers #Partners

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Product Stage #Expand

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

#Product Stage #Customers

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

#Product Stage #Partners

Sector Update: Health Care Stocks Mixed Thursday Afternoon

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

#Product Stage #FDA approved/pending approval

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

#Product Stage

Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial

#Product Stage #FDA approved/pending approval

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

#Product Stage #Customers

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

#Product Stage

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

#Partners

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

#Product Stage #Customers #Partners

Trump Trade: President said to weigh possible U.S. strike against Iran

Psychedelic advocates hopeful Trump administration will support space, STAT says

#Acquired-by #Acquisition

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

#Partners

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

#Product Stage

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

#Product Stage

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

#Product Stage #Partners

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

#Product Stage #Partners

Psychedelic: Clearmind completes clinical site initiations for AUD trial

#Product Stage #FDA approved/pending approval #Partners

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

#Product Stage

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

#Product Stage #FDA approved/pending approval

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

#Product Stage #FDA approved/pending approval

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

#Product Stage

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

#Product Stage #FDA approved/pending approval

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

#Product Stage #FDA approved/pending approval

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

#Product Stage

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

#Product Stage #Partners

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

#Product Stage

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

#Product Stage

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

#Product Stage

Psychedelic: atai Life Sciences, NRx report quarterly results

#Investment #Product Stage

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

#Partners #Product Stage

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

#Product Stage

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

#Product Stage #Customers

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

#Product Stage #Partners

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

#Product Stage #Partners

Psychedelic: GH Research, Compass Pathways report earnings results

#Product Stage #FDA approved/pending approval

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

#Product Stage #Partners

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

#Product Stage #Partners

Clearmind Medicine Announces Shareholders Meeting Results

#Management Changes #Product Stage

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

#Product Stage #Partners

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

#Partners #Product Stage

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Clearmind Medicine to move forward with MEAI-based alcohol substitute

#Partners

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

#Partners

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

#Partners

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

#Customers

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

#Partners

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

#Partners

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

#Partners

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

#Partners

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

#Partners

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Customers #Partners #Acquisition

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

#Investment

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

#Partners #Expand

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

#Partners

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

#Investment

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

#Partners

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

#Partners #Expand

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

#Investment #Expand

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

#Partners #Expand

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

#Partners #Expand

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

#Expand

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

#Partners #Expand

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

#Customers #Expand #Investment

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

#Investment #Expand #Management Changes

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

#Partners #Expand

Clearmind Applies to Cease Being a Reporting Issuer in Canada

#Public Trading

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

#Partners #Expand

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

#Investment

Clearmind Medicine CEO Issues Letter to Shareholders

#Partners #Expand

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

#Partners #Investment

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

#Investment

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

#Public Trading

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

#Customers #Partners

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

#Partners #Expand

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

#Partners

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

#Customers #Partners #Expand

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

#Customers #Partners #Expand

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

#Partners

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

#Partners #Expand

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

#Customers, Partners, Acquisition, Management Changes, Investment

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

#Customers #Partners #Investment #Acquisition #Public Trading #Management Changes #Layoffs #Expand

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

#Partners #Expand

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

#Investment

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

#Investment #Partners

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

#Investment

Clearmind Medicine Completed Type A Meeting with the FDA

#Customers #Investment

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

#Partners #Investment

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

#Partners

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

#Public Trading

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

#Partners #Investment

Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

#Partners

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

#Investment

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

#Partners, Expand

Clearmind Medicine Announces 1-for-30 Reverse Share Split

#Public Trading

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

#Public Trading #Management Changes

Clearmind Medicine Announces Shareholders Meeting Results

#Management Changes #Public Trading

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

#Partners #Expand

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th

#Management Changes

Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th

#Management Changes

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)

#Investment #Public Trading

Clearmind Medicine Closes US$2.25 Million Public Offering

#Investment #Public Trading

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

#Investment #Public Trading

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

#Partners #Expand

Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company

#Partners #Expand

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

#Partners #Expand

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

#Partners #Investment

Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

#Investment

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

#Management Changes

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

#Partners

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

#Partners

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

#Customers #Investment

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

#Customers

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

#Public Trading

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

#Customers #Partners

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants

#Partners #Investment

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

#Partners

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

#Partners

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial

#Partners #Investment

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

#Partners #Investment

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

#Partners

Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial

#Partners #Expand

Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND)

#Investment

Clearmind Medicine Closes US$3.5 Million Public Offering

#Investment #Public Trading

Clearmind Medicine Closes US$3.5 Million Public Offering

#Investment

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

#Public Trading #Investment

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

#Customers

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

#Management Changes

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

#Partners

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

#Partners

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

1/2021

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

Clearmind Medicine Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

Clearmind Medicine Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Public Offering

$2.25M

Sep 2023

Stock Exchange

NASDAQ

Valuation Undisclosed

$2.25M

Public Offering

$3.5M

Apr 2023

Stock Exchange

NASDAQ

Valuation Undisclosed

$3.5M

Public Offering

$7.5M

Nov 2022

Stock Exchange

NASDAQ

Valuation Undisclosed

$7.5M

Initial Public Offering EXIT

Undisclosed

Jun 2022

Stock Exchange

CSE

Valuation Undisclosed

Undisclosed

Private Equity Funding

PIPE

$560K

Nov 2025

$560K

PIPE

$2.4M

Jan 2024

1 Investors

$2.4M

Clearmind Medicine Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

PIPE

$560K

Nov 2025

$560K

PIPE

$2.4M

Jan 2024

1 Investors

$2.4M

Stock Exchange

NASDAQ

Valuation Undisclosed

$2.25M

Stock Exchange

NASDAQ

Valuation Undisclosed

$3.5M

Stock Exchange

NASDAQ

Valuation Undisclosed

$7.5M

Stock Exchange

CSE

Valuation Undisclosed

Undisclosed

News Over Time

News Articles